Freeline Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 oct. 2022 16h01 HE
|
Freeline Therapeutics Holdings plc
LONDON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on September 30, 2022, the Company granted five newly hired employees non-statutory...
Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190 Gene Therapy Candidate for People with Fabry Disease
04 oct. 2022 07h00 HE
|
Freeline Therapeutics Holdings plc
LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the first patient has been dosed in the second dose cohort of the Phase 1/2 MARVEL-1...
Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress
10 juil. 2022 03h00 HE
|
Freeline Therapeutics
FLT180a generated protective FIX levels with no bleeding or need for FIX replacement The treatment was well tolerated with a good safety profile LONDON, July 10, 2022 (GLOBE NEWSWIRE) -- Freeline...
Freeline Announces June 2022 Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 juil. 2022 16h01 HE
|
Freeline Therapeutics
LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on June 30, 2022, the Company granted a newly hired employee non-statutory options to...
Freeline Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
03 juin 2022 16h01 HE
|
Freeline Therapeutics
LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today disclosed the receipt of a notice (the “Notice”) on May 31, 2022 from...
Freeline Reports First Quarter 2022 Financial Results and Business Highlights
10 mai 2022 16h01 HE
|
Freeline Therapeutics
Phase 1/2 clinical programs in Hemophilia B, Gaucher disease and Fabry disease on track to deliver 2022 milestones Recent appointment of new Chief Financial Officer further strengthens leadership...
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 mai 2022 16h01 HE
|
Freeline Therapeutics
LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that on April 29, 2022, the Company granted five newly hired...
Freeline To Present at the 25th Annual Meeting of the American Society of Gene and Cell Therapy
02 mai 2022 17h10 HE
|
Freeline Therapeutics
LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced the upcoming presentation of five posters at the 25th Annual...
Freeline Appoints Paul Schneider as Chief Financial Officer
19 avr. 2022 08h01 HE
|
Freeline Therapeutics
LONDON, April 19, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that Paul M. Schneider has been appointed Chief Financial...
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 mars 2022 16h01 HE
|
Freeline Therapeutics
LONDON, March 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that on February 28, 2022, the Company granted three newly...